image
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 3.6
-1.37 %
$ 251 M
Market Cap
-3.13
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one HCAT stock under the worst case scenario is HIDDEN Compared to the current market price of 3.6 USD, Health Catalyst, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one HCAT stock under the base case scenario is HIDDEN Compared to the current market price of 3.6 USD, Health Catalyst, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one HCAT stock under the best case scenario is HIDDEN Compared to the current market price of 3.6 USD, Health Catalyst, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HCAT

image
$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
307 M REVENUE
3.60%
-69.8 M OPERATING INCOME
44.99%
-69.5 M NET INCOME
41.17%
14.6 M OPERATING CASH FLOW
144.01%
-22.9 M INVESTING CASH FLOW
-112.86%
152 M FINANCING CASH FLOW
5458.46%
79.4 M REVENUE
-0.24%
-20.2 M OPERATING INCOME
-15.26%
-23.7 M NET INCOME
-14.85%
280 K OPERATING CASH FLOW
107.94%
96.8 M INVESTING CASH FLOW
185.82%
-4.71 M FINANCING CASH FLOW
-12.50%
Balance Sheet Health Catalyst, Inc.
image
Current Assets 466 M
Cash & Short-Term Investments 392 M
Receivables 57.2 M
Other Current Assets 16.5 M
Non-Current Assets 393 M
Long-Term Investments 0
PP&E 41.5 M
Other Non-Current Assets 352 M
45.64 %6.66 %4.83 %40.96 %Total Assets$858.9m
Current Liabilities 326 M
Accounts Payable 11.4 M
Short-Term Debt 235 M
Other Current Liabilities 79.6 M
Non-Current Liabilities 168 M
Long-Term Debt 167 M
Other Non-Current Liabilities 403 K
47.56 %16.13 %33.92 %Total Liabilities$493.7m
EFFICIENCY
Earnings Waterfall Health Catalyst, Inc.
image
Revenue 307 M
Cost Of Revenue 166 M
Gross Profit 141 M
Operating Expenses 211 M
Operating Income -69.8 M
Other Expenses -304 K
Net Income -69.5 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)307m(166m)141m(211m)(70m)304k(70m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
45.92% GROSS MARGIN
45.92%
-22.77% OPERATING MARGIN
-22.77%
-22.67% NET MARGIN
-22.67%
-19.03% ROE
-19.03%
-8.09% ROA
-8.09%
-9.13% ROIC
-9.13%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Health Catalyst, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -69.5 M
Depreciation & Amortization 41.4 M
Capital Expenditures -16.4 M
Stock-Based Compensation 40.1 M
Change in Working Capital -660 K
Others -7.44 M
Free Cash Flow -1.84 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Health Catalyst, Inc.
image
Wall Street analysts predict an average 1-year price target for HCAT of $7.67 , with forecasts ranging from a low of $5 to a high of $11 .
HCAT Lowest Price Target Wall Street Target
5 USD 38.89%
HCAT Average Price Target Wall Street Target
7.67 USD 112.96%
HCAT Highest Price Target Wall Street Target
11 USD 205.56%
Price
Max Price Target
Min Price Target
Average Price Target
1111101099887766554433Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Health Catalyst, Inc.
image
Sold
0-3 MONTHS
66.8 K USD 2
3-6 MONTHS
299 K USD 3
6-9 MONTHS
782 K USD 6
9-12 MONTHS
248 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Health Catalyst (HCAT) Upgraded to Buy: Here's Why Health Catalyst (HCAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 weeks ago
Health Catalyst: Ignite Platform Is A Growth Catalyst I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT's large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management's FY25 guidance and signaling a potential inflection point for the business. seekingalpha.com - 3 weeks ago
Health Catalyst to Participate in Upcoming Investor Conferences SALT LAKE CITY, May 20, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jason Alger, Chief Financial Officer, and Jack Knight, Vice President of Investor Relations, will participate in the following upcoming investor conferences: The Stifel Cross Sector 1x1 Conference, being held in Boston, on Tuesday, June 3, 2025. The Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, on Tuesday, June 10, 2025. globenewswire.com - 1 month ago
Health Catalyst, Inc. (HCAT) Q1 2025 Earnings Call Transcript Health Catalyst, Inc. (NASDAQ:HCAT ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Jack Knight - Vice President, Investor Relations Dan Burton - Chief Executive Officer Dan LeSueur - Chief Operating Officer Jason Alger - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Jared Haase - William Blair Jessica Tassan - Piper Sandler Elizabeth Anderson - Evercore ISI Richard Close - Canaccord Genuity Daniel Grosslight - Citi Jenny Shen - BTIG Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Jeff Garro - Stephens Sarah James - Cantor Operator Welcome to the Health Catalyst First Quarter 2025 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for your questions following the presentation. seekingalpha.com - 1 month ago
Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Health Catalyst (HCAT) Q1 Earnings Meet Estimates Health Catalyst (HCAT) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. zacks.com - 1 month ago
Health Catalyst Reports First Quarter 2025 Results SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2025. “For the first quarter of 2025, I am pleased by our strong financial results, including total revenue of $79.4 million and Adjusted EBITDA of $6.3 million, with these results beating our quarterly guidance on each metric,” said Dan Burton, CEO of Health Catalyst. globenewswire.com - 1 month ago
Health Catalyst Announces Strategic Partnership with Microsoft to Accelerate AI Adoption and Transformation for Care Delivery Organizations Health Catalyst's Improvement Expertise Built on Microsoft Azure and Azure AI Foundry to Drive Reliable Insight and Sustained Outcomes for Care Providers SALT LAKE CITY , April 29, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced a strategic partnership with Microsoft to help healthcare organizations accelerate operational, clinical, and financial performance through AI-driven innovation. The collaboration further builds on Health Catalyst's expertise with Microsoft Azure and Azure AI Foundry capabilities, equipping healthcare organizations with advanced AI solutions to accelerate time to value, enhance care delivery, and drive measurable, long-term improvement. prnewswire.com - 2 months ago
Health Catalyst to Announce First Quarter 2025 Operating Results and Host Conference Call on Wednesday, May 7, 2025 SALT LAKE CITY, April 17, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2025 operating results on Wednesday, May 7, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day. globenewswire.com - 2 months ago
Beyond Tempus AI: 2 Health IT Stocks Poised for Growth in 2025 AI-driven healthcare companies like Butterfly Network and Health Catalyst have all the qualities to emerge as the next big players. zacks.com - 2 months ago
Health Catalyst Releases Data and Analytics Solution Designed for Community, Regional, and Specialty Health Systems: Health Catalyst Ignite Spark™ SALT LAKE CITY , April 10, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite Spark™, a tailored data and analytics solution built for community health systems, regional hospitals, and multi-site practices. Smaller community health systems across the U.S. are navigating shrinking margins, policy uncertainty, and rising pressure to deliver more with less. prnewswire.com - 2 months ago
Health Catalyst: Share Price Continues To Dismiss Positive Earnings And Improved Outlook Despite a 50% drop in HCAT's stock price, the company shows significant growth, reporting $307M in revenue and $26M in adjusted EBITDA for 2024. Health Catalyst focuses on efficiency, exiting lower-margin segments, and pushing AI-driven efficiencies, aiming for improved margins and profitability in 2025. The company forecasts strong growth with 40 new platform clients in 2025 and expects $335M in revenue, trading at a significant discount compared to industry peers. seekingalpha.com - 3 months ago
8. Profile Summary

Health Catalyst, Inc. HCAT

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 251 M
Dividend Yield 0.00%
Description Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Contact 10897 South River Front Parkway, South Jordan, UT, 84095 https://www.healthcatalyst.com
IPO Date July 25, 2019
Employees 1500
Officers Mr. Jeffrey P. Selander Senior Vice President of International Mr. Jason Alger Chief Financial Officer Mr. Kevin Freeman Chief Commercial Officer Ms. Amanda Flanders Senior Vice President of Marketing & Communications Mr. Benjamin Landry General Counsel & Secretary of the Board Mr. Kyle J. Salyers Chief Strategy Officer & Senior Vice President of Corporate Development Mr. Daniel D. Burton Chief Executive Officer & Director Mr. Daniel LeSueur Chief Operating Officer Mr. Dave Ross Chief Technology Officer Ms. Linda Llewelyn Chief People Officer